Antibody–Drug Conjugates: The Last Decade
An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylot...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/9/245 |
| _version_ | 1797553749749661696 |
|---|---|
| author | Nicolas Joubert Alain Beck Charles Dumontet Caroline Denevault-Sabourin |
| author_facet | Nicolas Joubert Alain Beck Charles Dumontet Caroline Denevault-Sabourin |
| author_sort | Nicolas Joubert |
| collection | DOAJ |
| description | An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg<sup>®</sup>) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. |
| first_indexed | 2024-03-10T16:21:02Z |
| format | Article |
| id | doaj.art-e6d9d8fd349c4623a1e0c931d2a827db |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T16:21:02Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-e6d9d8fd349c4623a1e0c931d2a827db2023-11-20T13:40:39ZengMDPI AGPharmaceuticals1424-82472020-09-0113924510.3390/ph13090245Antibody–Drug Conjugates: The Last DecadeNicolas Joubert0Alain Beck1Charles Dumontet2Caroline Denevault-Sabourin3GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, FranceInstitut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, FranceCancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, FranceGICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, FranceAn armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg<sup>®</sup>) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of.https://www.mdpi.com/1424-8247/13/9/245antibody–drug conjugateADCbioconjugationlinkerpayloadcancer |
| spellingShingle | Nicolas Joubert Alain Beck Charles Dumontet Caroline Denevault-Sabourin Antibody–Drug Conjugates: The Last Decade Pharmaceuticals antibody–drug conjugate ADC bioconjugation linker payload cancer |
| title | Antibody–Drug Conjugates: The Last Decade |
| title_full | Antibody–Drug Conjugates: The Last Decade |
| title_fullStr | Antibody–Drug Conjugates: The Last Decade |
| title_full_unstemmed | Antibody–Drug Conjugates: The Last Decade |
| title_short | Antibody–Drug Conjugates: The Last Decade |
| title_sort | antibody drug conjugates the last decade |
| topic | antibody–drug conjugate ADC bioconjugation linker payload cancer |
| url | https://www.mdpi.com/1424-8247/13/9/245 |
| work_keys_str_mv | AT nicolasjoubert antibodydrugconjugatesthelastdecade AT alainbeck antibodydrugconjugatesthelastdecade AT charlesdumontet antibodydrugconjugatesthelastdecade AT carolinedenevaultsabourin antibodydrugconjugatesthelastdecade |